Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Eng

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
British Journal of Sports Medicine|April 23, 2017
Aerobic exercise promotes executive functions and impacts functional neural activity among older adults with vascular cognitive impairmentChun Liang Hsu, John R Best, Jennifer C Davis, et al.
Clinical and Translational Science|March 4, 2026
Evaluation of the Effect of Food and Formulation on the Pharmacokinetics of the SHP2 Inhibitor Migoprotafib Within a Phase I Study in Cancer PatientsJulia Suchomel, Christine M Bowman, Po-Chang Chiang, et al.
Breast Cancer Research and Treatment|October 27, 2010
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancerClaudine Isaacs, Pia Herbolsheimer, Minetta C Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancerMinetta C Liu, Peter G Shields, Robert D Warren, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2016
Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and SafetyMargaret E Gatti-Mays, David Venzon, Claudia E Galbo, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 10, 2012
Patient navigation significantly reduces delays in breast cancer diagnosis in the District of ColumbiaHeather J Hoffman, Nancy L LaVerda, Heather A Young, et al.
Clinical Breast Cancer|January 12, 2020
Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast CancerJosé Bines, Marion Procter, Eleonora Restuccia, et al.
Molecular Cancer Research : MCR|January 14, 2021
Genomic Alterations during the <i>In Situ</i> to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune SystemAnne Trinh, Carlos R Gil Del Alcazar, Sachet A Shukla, et al.
Breast Cancer Research : BCR|February 11, 2017
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancerGiampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, et al.
Nature Cancer|January 13, 2025
ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER<sup>+</sup> breast cancerJackson Liang, Xiaosai Yao, Patrick Aouad, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
British Journal of Sports Medicine|April 23, 2017
Aerobic exercise promotes executive functions and impacts functional neural activity among older adults with vascular cognitive impairmentChun Liang Hsu, John R Best, Jennifer C Davis, et al.
Clinical and Translational Science|March 4, 2026
Evaluation of the Effect of Food and Formulation on the Pharmacokinetics of the SHP2 Inhibitor Migoprotafib Within a Phase I Study in Cancer PatientsJulia Suchomel, Christine M Bowman, Po-Chang Chiang, et al.
Breast Cancer Research and Treatment|October 27, 2010
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancerClaudine Isaacs, Pia Herbolsheimer, Minetta C Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancerMinetta C Liu, Peter G Shields, Robert D Warren, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2016
Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and SafetyMargaret E Gatti-Mays, David Venzon, Claudia E Galbo, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 10, 2012
Patient navigation significantly reduces delays in breast cancer diagnosis in the District of ColumbiaHeather J Hoffman, Nancy L LaVerda, Heather A Young, et al.
Clinical Breast Cancer|January 12, 2020
Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast CancerJosé Bines, Marion Procter, Eleonora Restuccia, et al.
Molecular Cancer Research : MCR|January 14, 2021
Genomic Alterations during the <i>In Situ</i> to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune SystemAnne Trinh, Carlos R Gil Del Alcazar, Sachet A Shukla, et al.
Breast Cancer Research : BCR|February 11, 2017
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancerGiampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, et al.
Nature Cancer|January 13, 2025
ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER<sup>+</sup> breast cancerJackson Liang, Xiaosai Yao, Patrick Aouad, et al.
Pageof 7